Nkarta - Model NKX019 - Proprietary CD19 Binder

For patients with many B-cell malignancies, there remains a substantial unmet medical need today.

• Large opportunity remains despite approved autologous CAR-T products:
  • Gr3+ cytokine release syndrome (CRS): 13-49%
  • Gr3+ neurotoxicity: 18-31%
  • Limited number of specialized sites can treat
• Compelling commercial opportunity